Clinical Trial Update: Efficacy and Safety of Imatinib in Scleroderma [Phase 2]

View source ↗

Summary

Phase 2 trial of imatinib in systemic sclerosis and localized scleroderma has completed, with reported efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Localized Scleroderma
• Systemic Sclerosis

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Scleroderma, Localized, Scleroderma, Systemic | Phase 2 | Status: COMPLETED